aTYR PHARMA (ATYR) Income from Continuing Operations (2014 - 2026)
aTYR PHARMA's (ATYR) quarterly Income from Continuing Operations came in at 13471000.0 in Q1 2026, up 24.21% YoY from 10845384.52 in Q1 2025, and up 9.07% on a QoQ basis from 14815000.0 in Q4 2025.
aTYR PHARMA (ATYR) Income from Continuing Operations (2014 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has 13 years of Income from Continuing Operations data on file, last reported at 13471000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 24.21% year-over-year to 13471000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 79303000.0 (down 3.11% YoY) and the FY2025 annual result came in at 219827000.0, down 14.43% from the prior year.
- Income from Continuing Operations improved to 13471000.0 in Q1 2026, from 14815000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 8004000.0 in Q4 2022 to a low of 28720000.0 in Q3 2025.
- A 5-year average of 18168294.12 and a median of 19085000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 91.39% in 2022, down 159.23% in 2022.
- Tracing ATYR's Income from Continuing Operations over 5 years: stood at 8004000.0 in 2022, then slumped by 99.88% to 15998000.0 in 2023, then increased by 0.93% to 15850000.0 in 2024, then advanced by 6.53% to 14815000.0 in 2025, then grew by 9.07% to 13471000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 13471000.0 (Q1 2026), 14815000.0 (Q4 2025), and 28720000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | aTYR PHARMA | 49.54 Mn | -7.87 Mn | - | -10.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.91 Mn |
| Mar 31, 2026 | -13.47 Mn |
| Dec 31, 2025 | -14.82 Mn |
| Sep 30, 2025 | -28.72 Mn |
| Jun 30, 2025 | -22.30 Mn |
| Mar 31, 2025 | -17.77 Mn |
| Dec 31, 2024 | -15.85 Mn |
| Sep 30, 2024 | -20.06 Mn |
| Jun 30, 2024 | -23.23 Mn |
| Mar 31, 2024 | -22.89 Mn |
| Dec 31, 2023 | -16.00 Mn |
| Sep 30, 2023 | -19.09 Mn |
| Jun 30, 2023 | -20.04 Mn |
| Mar 31, 2023 | -19.28 Mn |
| Dec 31, 2022 | -8.00 Mn |
| Sep 30, 2022 | -20.37 Mn |
| Jun 30, 2022 | -13.39 Mn |
| Mar 31, 2022 | -13.58 Mn |
| Dec 31, 2021 | -92.93 Mn |
| Sep 30, 2021 | -7.86 Mn |